Old Web
English
Sign In
Acemap
>
authorDetail
>
Hemant Patel
Hemant Patel
Roswell Park Cancer Institute
Neutropenia
Immunology
Chemotherapy
Medicine
Calicheamicin
3
Papers
84
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study
2008
Blood
Luis Fayad
Hemant Patel
Gregor Verhoef
Mitchell R. Smith
Peter Johnson
Myron S. Czuczman
B Coiffier
Georg Hess
Eva Giné
Anjali S. Advani
Fritz Offner
Erik Vandendries
Mark Shapiro
Nam H. Dang
Show All
Source
Cite
Save
Citations (30)
Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.
2006
Blood
Luis Fayad
Hemant Patel
Gregor Verhoef
Myron S. Czuczman
James M. Foran
Eva Giné
Ama Rohatiner
Mitchell R. Smith
Mark Shapiro
Anjali S. Advani
Show All
Source
Cite
Save
Citations (32)
Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).
2005
Blood
Anjali S. Advani
Eva Giné
Christian Gisselbrecht
Ama Rohatiner
Steven D. Rosen
Mitchell R. Smith
Joseph Boni
Chantal Lejeune
Hemant Patel
Show All
Source
Cite
Save
Citations (22)
1